NASDAQ:BASI

Bioanalytical Systems Competitors

$19.22
-1.27 (-6.20 %)
(As of 04/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.40
Now: $19.22
$19.89
50-Day Range
$14.04
MA: $18.74
$22.50
52-Week Range
$3.05
Now: $19.22
$21.08
Volume644,549 shs
Average Volume122,925 shs
Market Capitalization$213.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.92

Competitors

Bioanalytical Systems (NASDAQ:BASI) Vs. IQV, EXAS, INCY, CRL, PPD, and ICLR

Should you be buying BASI stock or one of its competitors? Companies in the industry of "commercial physical research" are considered alternatives and competitors to Bioanalytical Systems, including IQVIA (IQV), Exact Sciences (EXAS), Incyte (INCY), Charles River Laboratories International (CRL), PPD (PPD), and ICON Public (ICLR).

Bioanalytical Systems (NASDAQ:BASI) and IQVIA (NYSE:IQV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Institutional & Insider Ownership

10.6% of Bioanalytical Systems shares are held by institutional investors. Comparatively, 87.2% of IQVIA shares are held by institutional investors. 11.5% of Bioanalytical Systems shares are held by insiders. Comparatively, 6.0% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Bioanalytical Systems and IQVIA's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioanalytical Systems$60.47 million3.54$-4,680,000.00($0.35)-54.91
IQVIA$11.09 billion3.89$191 million$5.9437.86

IQVIA has higher revenue and earnings than Bioanalytical Systems. Bioanalytical Systems is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bioanalytical Systems has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Bioanalytical Systems and IQVIA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioanalytical Systems00103.00
IQVIA011302.93

Bioanalytical Systems presently has a consensus price target of $17.00, suggesting a potential downside of 11.55%. IQVIA has a consensus price target of $208.60, suggesting a potential downside of 7.80%. Given IQVIA's higher probable upside, analysts plainly believe IQVIA is more favorable than Bioanalytical Systems.

Profitability

This table compares Bioanalytical Systems and IQVIA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bioanalytical Systems-7.75%-42.74%-6.38%
IQVIA1.61%18.03%4.64%

Summary

IQVIA beats Bioanalytical Systems on 11 of the 14 factors compared between the two stocks.

Bioanalytical Systems (NASDAQ:BASI) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Bioanalytical Systems and Exact Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bioanalytical Systems-7.75%-42.74%-6.38%
Exact Sciences-25.27%-11.71%-6.74%

Analyst Ratings

This is a summary of recent recommendations for Bioanalytical Systems and Exact Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioanalytical Systems00103.00
Exact Sciences031102.79

Bioanalytical Systems presently has a consensus price target of $17.00, suggesting a potential downside of 11.55%. Exact Sciences has a consensus price target of $150.3333, suggesting a potential upside of 14.27%. Given Exact Sciences' higher probable upside, analysts plainly believe Exact Sciences is more favorable than Bioanalytical Systems.

Valuation & Earnings

This table compares Bioanalytical Systems and Exact Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioanalytical Systems$60.47 million3.54$-4,680,000.00($0.35)-54.91
Exact Sciences$876.29 million25.16$-83,990,000.00($1.49)-87.50

Bioanalytical Systems has higher earnings, but lower revenue than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Bioanalytical Systems, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

10.6% of Bioanalytical Systems shares are held by institutional investors. Comparatively, 90.4% of Exact Sciences shares are held by institutional investors. 11.5% of Bioanalytical Systems shares are held by insiders. Comparatively, 1.8% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Bioanalytical Systems has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.

Summary

Bioanalytical Systems beats Exact Sciences on 8 of the 14 factors compared between the two stocks.

Incyte (NASDAQ:INCY) and Bioanalytical Systems (NASDAQ:BASI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Incyte and Bioanalytical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Incyte-13.62%-13.66%-9.98%
Bioanalytical Systems-7.75%-42.74%-6.38%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Incyte and Bioanalytical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Incyte18902.44
Bioanalytical Systems00103.00

Incyte presently has a consensus price target of $100.8462, suggesting a potential upside of 20.13%. Bioanalytical Systems has a consensus price target of $17.00, suggesting a potential downside of 11.55%. Given Incyte's higher probable upside, equities research analysts clearly believe Incyte is more favorable than Bioanalytical Systems.

Valuation and Earnings

This table compares Incyte and Bioanalytical Systems' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incyte$2.16 billion8.53$446.91 million$2.2337.55
Bioanalytical Systems$60.47 million3.54$-4,680,000.00($0.35)-54.91

Incyte has higher revenue and earnings than Bioanalytical Systems. Bioanalytical Systems is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

91.4% of Incyte shares are held by institutional investors. Comparatively, 10.6% of Bioanalytical Systems shares are held by institutional investors. 16.1% of Incyte shares are held by insiders. Comparatively, 11.5% of Bioanalytical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Incyte has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500.

Summary

Incyte beats Bioanalytical Systems on 9 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and Bioanalytical Systems (NASDAQ:BASI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Charles River Laboratories International and Bioanalytical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories International10.68%22.41%7.66%
Bioanalytical Systems-7.75%-42.74%-6.38%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Charles River Laboratories International and Bioanalytical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International031102.79
Bioanalytical Systems00103.00

Charles River Laboratories International presently has a consensus price target of $254.7143, suggesting a potential downside of 22.58%. Bioanalytical Systems has a consensus price target of $17.00, suggesting a potential downside of 11.55%. Given Bioanalytical Systems' stronger consensus rating and higher probable upside, analysts clearly believe Bioanalytical Systems is more favorable than Charles River Laboratories International.

Valuation and Earnings

This table compares Charles River Laboratories International and Bioanalytical Systems' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$2.62 billion6.30$252.02 million$6.7348.87
Bioanalytical Systems$60.47 million3.54$-4,680,000.00($0.35)-54.91

Charles River Laboratories International has higher revenue and earnings than Bioanalytical Systems. Bioanalytical Systems is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.3% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 10.6% of Bioanalytical Systems shares are held by institutional investors. 1.9% of Charles River Laboratories International shares are held by insiders. Comparatively, 11.5% of Bioanalytical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Charles River Laboratories International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500.

Summary

Charles River Laboratories International beats Bioanalytical Systems on 10 of the 14 factors compared between the two stocks.

PPD (NASDAQ:PPD) and Bioanalytical Systems (NASDAQ:BASI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for PPD and Bioanalytical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PPD011402.27
Bioanalytical Systems00103.00

PPD presently has a consensus price target of $42.1818, suggesting a potential downside of 8.60%. Bioanalytical Systems has a consensus price target of $17.00, suggesting a potential downside of 11.55%. Given PPD's higher probable upside, equities research analysts clearly believe PPD is more favorable than Bioanalytical Systems.

Institutional and Insider Ownership

68.8% of PPD shares are held by institutional investors. Comparatively, 10.6% of Bioanalytical Systems shares are held by institutional investors. 11.5% of Bioanalytical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares PPD and Bioanalytical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PPD0.21%-11.06%2.75%
Bioanalytical Systems-7.75%-42.74%-6.38%

Valuation and Earnings

This table compares PPD and Bioanalytical Systems' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PPD$4.03 billion4.01$47.82 million$0.9847.10
Bioanalytical Systems$60.47 million3.54$-4,680,000.00($0.35)-54.91

PPD has higher revenue and earnings than Bioanalytical Systems. Bioanalytical Systems is trading at a lower price-to-earnings ratio than PPD, indicating that it is currently the more affordable of the two stocks.

Summary

PPD beats Bioanalytical Systems on 11 of the 13 factors compared between the two stocks.

Bioanalytical Systems (NASDAQ:BASI) and ICON Public (NASDAQ:ICLR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Bioanalytical Systems and ICON Public, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bioanalytical Systems00103.00
ICON Public04702.64

Bioanalytical Systems presently has a consensus target price of $17.00, suggesting a potential downside of 11.55%. ICON Public has a consensus target price of $219.90, suggesting a potential upside of 4.08%. Given ICON Public's higher probable upside, analysts clearly believe ICON Public is more favorable than Bioanalytical Systems.

Institutional and Insider Ownership

10.6% of Bioanalytical Systems shares are owned by institutional investors. Comparatively, 81.7% of ICON Public shares are owned by institutional investors. 11.5% of Bioanalytical Systems shares are owned by company insiders. Comparatively, 44.0% of ICON Public shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Bioanalytical Systems has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Profitability

This table compares Bioanalytical Systems and ICON Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bioanalytical Systems-7.75%-42.74%-6.38%
ICON Public11.95%21.42%11.85%

Valuation & Earnings

This table compares Bioanalytical Systems and ICON Public's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioanalytical Systems$60.47 million3.54$-4,680,000.00($0.35)-54.91
ICON Public$2.81 billion4.04$373.99 million$6.8830.69

ICON Public has higher revenue and earnings than Bioanalytical Systems. Bioanalytical Systems is trading at a lower price-to-earnings ratio than ICON Public, indicating that it is currently the more affordable of the two stocks.

Summary

ICON Public beats Bioanalytical Systems on 12 of the 14 factors compared between the two stocks.


Bioanalytical Systems Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IQVIA logo
IQV
IQVIA
1.7$224.88-2.6%$42.00 billion$11.09 billion247.12Earnings Announcement
Analyst Upgrade
Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Exact Sciences logo
EXAS
Exact Sciences
1.8$130.37-1.2%$21.77 billion$876.29 million-58.99Analyst Upgrade
Incyte logo
INCY
Incyte
1.6$83.73-1.2%$18.63 billion$2.16 billion-53.33Analyst Revision
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$328.88-1.5%$16.27 billion$2.62 billion54.81Analyst Downgrade
PPD logo
PPD
PPD
1.7$46.16-0.0%$16.17 billion$4.03 billion307.73Upcoming Earnings
Analyst Downgrade
ICON Public logo
ICLR
ICON Public
2.0$211.15-0.2%$11.30 billion$2.81 billion35.19Upcoming Earnings
Increase in Short Interest
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.4$164.80-0.4%$10.59 billion$3.07 billion48.19Upcoming Earnings
Analyst Downgrade
Analyst Revision
News Coverage
Syneos Health logo
SYNH
Syneos Health
1.6$88.66-0.8%$9.17 billion$4.68 billion48.71Upcoming Earnings
Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$24.81-0.6%$7.72 billion$967.78 million51.69Analyst Report
Medpace logo
MEDP
Medpace
1.2$186.23-1.0%$6.77 billion$860.97 million56.95Upcoming Earnings
Insider Selling
News Coverage
Precigen logo
PGEN
Precigen
1.7$8.40-2.7%$1.68 billion$90.72 million-4.47Analyst Upgrade
National Research logo
NRC
National Research
0.8$48.23-0.4%$1.22 billion$127.98 million32.81
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
1.3$11.78-1.9%$840.37 millionN/A-26.18
Luna Innovations logo
LUNA
Luna Innovations
1.5$11.18-0.6%$353.23 million$70.52 million62.11
Pieris Pharmaceuticals logo
PIRS
Pieris Pharmaceuticals
1.4$2.28-2.2%$139.15 million$46.28 million-4.30
Eloxx Pharmaceuticals logo
ELOX
Eloxx Pharmaceuticals
1.4$2.30-4.8%$96.92 millionN/A-2.30
Cleveland BioLabs logo
CBLI
Cleveland BioLabs
0.6$5.03-1.6%$76.57 million$1.11 million0.00
AIkido Pharma logo
AIKI
AIkido Pharma
0.6$0.92-10.9%$32.07 million$10,000.000.00News Coverage
Tenax Therapeutics logo
TENX
Tenax Therapeutics
1.4$1.84-0.5%$27.69 millionN/A-1.52
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.